Regarding FXR agonists, the semisynthetic compound INT-747 (6-ethyl-CDCA or obeticolic acid) exerts a hepatoprotective effect in fibrosis [151], and protects against IR and hepatic steatosis [145]. This evidence concerns the gene NR1H4 and fatty liver disease.